Allena Pharmaceuticals and Althea Technologies have entered a licensing agreement under which Allena has obtained exclusive worldwide rights to Althea’s hyperoxaluria portfolio, including product patents, regulatory information and development data related to oxalate degrading enzymes. This license agreement strengthens Allena’s ongoing R&D activities for ALLN-177, its orally delivered enzyme therapy, and helps advance the company’s clinical development program for patients with hyperoxalur...